The new Gocap, which was invented by the company's co-founders James White and Richard Whalley, is currently under clinical studies to test its viability,
It will place insulin intake data on an app and in the cloud to enable patients better manage their regimen.
The cap will provide doctors with detail information about patients’ insulin habits and how they affect blood-glucose levels for better treatment.
Common Sensing also collaborated with Boston-based Joslin Diabetes Center to collect data on 125 patients using the cap over the next year.
The patient can replace the plastic cap with a Gocap while using the new pen. It uses an optical measurement method to measure the insulin volume in the pen.
Gocap will record the volume remaining and the time of the dose each time, when the the cap is removed and replaced. It is displayed on a digital screen.
The cap will also measure the temperature of the insulin that can deteriorate at high temperatures.
Gocap’s digital component helps in the tracking and analysis insulin. After each use, the device logs data from the pen through Bluetooth to a mobile app, and sends it to the cloud.
On the app, patients can place information about insulin type, meals and glucose levels from their glucometer.
White said: “We can alert people to the fact that they may be storing insulin too hot, which could seriously affect how they use it and how much effect it has on their body.
Image: Common Sensing co-founders James White and Richard Whalley. Photo: courtesy of Ian MacLellan.
